Trials / Recruiting
RecruitingNCT07096128
A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer
A Phase I Study to Assess the Safety, Tolerability, Radiation Dosimetry and Efficacy of [177Lu] Lu-PSMA-XT in Patients With Metastatic Prostate Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- Sponsor
- Jinming Zhang · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a multicenter, open-label, phase I study to evaluate the safety, tolerability, radiation dosimetry and efficacy of \[177Lu\] Lu-PSMA-XT injection in patients with metastatic prostate cancer .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [177Lu]Lu-PSMA-XT | \[177Lu\]Lu-PSMA-XT is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells. |
Timeline
- Start date
- 2024-08-20
- Primary completion
- 2026-05-31
- Completion
- 2027-04-30
- First posted
- 2025-07-31
- Last updated
- 2025-07-31
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07096128. Inclusion in this directory is not an endorsement.